Inflammatory Markers in Patients of Heart Attack
- Conditions
- Health Condition 1: null- ST Elevation Myocardial Infarction
- Registration Number
- CTRI/2015/06/005911
- Lead Sponsor
- CMC fluid research funding
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 102
Patients with age more than 18 years, presented with acute ST elevation myocardial infarction (STEMI) and eligible for reperfusion therapy as per STEMI protocol will be included in the study after taking informed consent. Acute STEMI will be diagnosed based on universal de�nition of myocardial infarction.
• STEMI patients in whom thrombolysis or primary PTCA not indicated according to guidelines like late presentation
• STEMI patients undergo Pharmacoinvasive PTCA
• Patients with acute or chronic inflammatory diseases, those with bacterial infections & sepsis and patients taking steroidal or non-steroidal anti-inflammatory drugs
• Patients with significant underlying other systemic disorders like chronic renal or hepatic or respiratory failure and malignancy
• Patients underwent any surgery in the last 4 weeks before STEMI
• Pregnant female presented with STEMI
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine serum procalcitonin level variation in 2 main modalities of treatment of STEMI(ST-segment Elevation Myocardial Infarction)- Thrombolysis & Primary PTCA (Percutaneous Transluminal Coronary Angioplasty)Timepoint: 24 Hours after hospital admission
- Secondary Outcome Measures
Name Time Method In-hospital outcomes like complications of STEMI & mortalityTimepoint: Duration of in-hospital stay